Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
Authors
Keywords
Dipeptidyl peptidase-4, Elderly, Renal impairment, Type 2 diabetes, Vildagliptin
Journal
Diabetes Therapy
Volume 4, Issue 2, Pages 257-267
Publisher
Springer Nature
Online
2013-07-02
DOI
10.1007/s13300-013-0027-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
- (2013) W David Strain et al. LANCET
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Trends in the quality of care for elderly people with type 2 diabetes: The need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys)
- (2011) Carole Pornet et al. DIABETES & METABOLISM
- European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary
- (2011) Alan J. Sinclair et al. DIABETES & METABOLISM
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- (2011) V. Lukashevich et al. DIABETES OBESITY & METABOLISM
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
- (2011) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management
- (2011) Sylvie Dejager et al. Diabetes Therapy
- Role of vildagliptin in managing type 2 diabetes mellitus in the elderly
- (2010) S. Halimi et al. CURRENT MEDICAL RESEARCH AND OPINION
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease
- (2009) M. F. Moen et al. Clinical Journal of the American Society of Nephrology
- Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes
- (2009) J. P. Bremer et al. DIABETES CARE
- Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
- (2009) Bo Ahrén et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now